150 related articles for article (PubMed ID: 17727318)
21. Assessment of markers of thrombin generation in patients with acute myocardial infarction complicated by ventricular fibrillation.
Elmas E; Kaelsch T; Wolpert C; Sueselbeck T; Bertsch T; Dempfle CE; Borggrefe M
Clin Cardiol; 2006 Apr; 29(4):165-9. PubMed ID: 16649726
[TBL] [Abstract][Full Text] [Related]
22. In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers.
Giansante C; Fiotti N; Di Chiara A; Altamura N; Wasserman S; Fioretti P; Guarnieri G
J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):602-7. PubMed ID: 17667031
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of right atrial matrix metalloproteinase expression between patients with unstable angina and myocardial infarction].
Wang W; Wu PS; Yang XL
Zhonghua Xin Xue Guan Bing Za Zhi; 2010 May; 38(5):411-4. PubMed ID: 20654099
[TBL] [Abstract][Full Text] [Related]
24. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome.
Inokubo Y; Hanada H; Ishizaka H; Fukushi T; Kamada T; Okumura K
Am Heart J; 2001 Feb; 141(2):211-7. PubMed ID: 11174334
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor [corrected] of matrix metalloproteinase-1 in myocardial infarction.
Guzel S; Serin O; Guzel EC; Buyuk B; Yılmaz G; Güvenen G
Korean J Intern Med; 2013 Mar; 28(2):165-73. PubMed ID: 23525523
[TBL] [Abstract][Full Text] [Related]
26. [In vivo interleukin-10 gene transfer down-regulates myocardial matrix metalloproteinase and myocardial collagen expressions in rats with acute myocardial infarction].
Hu CY; Ding WH; Han XN; Chu SY; Hao YJ; Bu DF
Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Mar; 36(3):243-8. PubMed ID: 19099983
[TBL] [Abstract][Full Text] [Related]
27. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
Kosmala W; Plaksej R; Przewlocka-Kosmala M; Kuliczkowska-Plaksej J; Bednarek-Tupikowska G; Mazurek W
Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181
[TBL] [Abstract][Full Text] [Related]
28. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration.
Tziakas DN; Chalikias GK; Parissis JT; Hatzinikolaou EI; Papadopoulos ED; Tripsiannis GA; Papadopoulou EG; Tentes IK; Karas SM; Chatseras DI
Int J Cardiol; 2004 Apr; 94(2-3):269-77. PubMed ID: 15093992
[TBL] [Abstract][Full Text] [Related]
29. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
Hoffmann U; Bertsch T; Dvortsak E; Liebetrau C; Lang S; Liebe V; Huhle G; Borggrefe M; Brueckmann M
Scand J Infect Dis; 2006; 38(10):867-72. PubMed ID: 17008230
[TBL] [Abstract][Full Text] [Related]
30. Expression of the tissue inhibitor of metalloproteinase-3 by transplanted VSMCs modifies heart structure and function after myocardial infarction.
Jia ZB; Tian H; Kang K; Miao HZ; Liu KY; Jiang SL; Wang LP
Transpl Immunol; 2014 May; 30(4):149-58. PubMed ID: 24727088
[TBL] [Abstract][Full Text] [Related]
31. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
Ulrich D; Hrynyschyn K; Pallua N
Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
[TBL] [Abstract][Full Text] [Related]
32. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents.
Głowińska-Olszewska B; Urban M
Metabolism; 2007 Jun; 56(6):799-805. PubMed ID: 17512313
[TBL] [Abstract][Full Text] [Related]
33. MMP-9 and Its Regulators TIMP-1 and EMMPRIN in Patients with Acute ST-Elevation Myocardial Infarction: A NORDISTEMI Substudy.
Opstad TB; Seljeflot I; Bøhmer E; Arnesen H; Halvorsen S
Cardiology; 2018; 139(1):17-24. PubMed ID: 29141241
[TBL] [Abstract][Full Text] [Related]
34. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
Gonçalves FM; Jacob-Ferreira AL; Gomes VA; Casella-Filho A; Chagas AC; Marcaccini AM; Gerlach RF; Tanus-Santos JE
Clin Chim Acta; 2009 May; 403(1-2):173-7. PubMed ID: 19254704
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[TBL] [Abstract][Full Text] [Related]
36. Serum tissue-degrading proteinases and incident cardiovascular disease events.
Tuomainen AM; Kormi I; Havulinna AS; Tervahartiala T; Salomaa V; Sorsa T; Pussinen PJ
Eur J Prev Cardiol; 2014 Jul; 21(7):806-12. PubMed ID: 23079500
[TBL] [Abstract][Full Text] [Related]
37. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of plasma matrix metalloproteinase-9 level in predicting future coronary revascularization in patients after acute myocardial infarction.
Wang KF; Huang PH; Chiang CH; Hsu CY; Leu HB; Chen JW; Lin SJ
Coron Artery Dis; 2013 Jan; 24(1):23-8. PubMed ID: 23151854
[TBL] [Abstract][Full Text] [Related]
39. The balance of serum matrix metalloproteinase-8 and its tissue inhibitor in acute coronary syndrome and its recurrence.
Pussinen PJ; Sarna S; Puolakkainen M; Öhlin H; Sorsa T; Pesonen E
Int J Cardiol; 2013 Jul; 167(2):362-8. PubMed ID: 22257687
[TBL] [Abstract][Full Text] [Related]
40. [Plasma matrix metalloproteinases MMP-2 and MMP-9 and tissue inhibitors TIMP-1 and TIMP-2 in children treated for acute lymphoblastic leukemia].
Krawczuk-Rybak M; Kuźmicz M; Mroczko B; Szmitkowski M
Pol Merkur Lekarski; 2010 Jul; 29(169):14-8. PubMed ID: 20712241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
